Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility

Neurology

Volumn 38, Issue 3, 1988, Pages 419-421

  Kurlan, R ^a   Rothfield, K P ^a   Woodward, W R ^b   Nutt, J G ^b   Miller, C ^a   Lichter, D ^a   Shoulson, I ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; CASE REPORT; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; STOMACH EMPTYING;

ABSORPTION; ADMINISTRATION, ORAL; CASE REPORT; DIHYDROXYPHENYLALANINE; DUODENUM; GASTRIC EMPTYING; HUMAN; INTUBATION; LEVODOPA; MALE; MIDDLE AGE; NOSE; PARKINSON DISEASE;

EID: 0023869464     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.38.3.419     Document Type: Article

References (21)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson’s disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1981:96-122.
2. Fahn S. Fluctuations of disability in Parkinson’s disease: pathophysiology. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1981:123-145.
3. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism. Ann Neurol 1986;20:262-265.
4. Nutt JG, Woodward WR, Hamerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Bngl J Med 1984;310:483-484.
5. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34:1131-1136.
6. Shoulson I, Glubiger GA, Chase TN. On-off responses: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-1148.
7. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neu- ropharmacol 1984;7:35-50.
8. Nutt JG, Woodward WR, Carter JH. Clinical and biochemical studies with controlled-release levodopazcarbidopa. Neurology 1986;36:1206-1211.
9. McDowell FH, Sweet RD. The on-off phenomenon. In: Birkmayer W, Homykiewicz O, eds Advances in parkinsonism. Basle: Editions Roche, 1976:603-612.
10. Muenter MD, DiNapoli RP, Sharpless NS, Tyce GM. 3-O-meth- yldopa, L-dopa and trihexyphenidyl in the treatment of Parkinson’s disease. Mayo Clin Proc 1973;48:173-183.
11. Rivera-Calimlim L, Tandon D, Anderson F, Joynt R. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders: treatment with levodopa and decarboxylase inhibitor. Arch Neurol 1977;34:28-32.
12. Feueretein C, Tanche M, Serre F, Gavend M, Pellat J, Perret J. Does O-methyldopa play a role in levodopa-induced dyskinesias? Acta Neurol Scand 1977;56:79-82.
13. Marsden CD. “On-off” phenomenon in Parkinson’s disease. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson’s disease: current progress, problems and management. Amsterdam: Elsevier North Holland, 1980:241-254.
14. Tolosa ES, Martin WE, Cohen JP, Jacobson RL. Patterns of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 1975;25:177-183.
15. Fahn S. Episodic failure of absorption of levodopa: a factor in the control of clinical fluctuations in the treatment of parkinsonism. Neurology 1977;27(suppl 2):390.
16. Melamed E, Bitton V, Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 1986;36:100-103.
17. Bianchine JR, Calimlim LR, Morgan JP, et al. Metabolism and absorption of l-3,4 dihydroxyphenylalanine in patients with Parkinson’s disease. Ann NY Acad Sci 1971;179:126-140.
18. Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. L-dopa treatment failure: explanation and correction. Br Med J 1970;4:93-94.
19. Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Tra- vert N. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975;25:1029-1034.
20. Mearrick PT, Wade DN, Birkett DJ, Morris J. Metoclopramide, gastric emptying and L-dopa. Aust NZ J Med 1974;4:144-148.
21. Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest 1971;1:313-320.